Pharmacotherapy of Sjogren’s syndrome: A comparison of disease activity with Iscalimab and Ianalumab

Sjögren's Syndrome is a disease that affects millions worldwide. Research indicates that people suffering from Sjögren's Syndrome respond well to monoclonal antibody treatment aimed at characteristic immune cell markers. By targeting immune cell markers, the immune system is subsequently suppressed in a way such that disease activity is decreased. Monoclonal antibody treatments targeted towards a variety of immune cell markers have historically been shown to result in decreases in Sjögren's Syndrome disease activity. Many studies have assessed disease activity with monoclonal antibody treatments, but few have compared different treatments. A systematic review of a study that assessed the disease activity for those taking iscalimab was then compared to the findings of another study which assessed the disease activity with those taking ianalumab. The patients treated with iscalimab had significantly decreased Sjögren's Syndrome disease when compared with other matched controls. Those who were treated with ianalumab had significantly decreased disease activity when compared with other matched controls. However, those who were treated with iscalimab had a greater reduction of disease activity as compared to control groups than did those who were treated with ianalumab. Monoclonal antibody treatments for Sjögren's Syndrome are widespread. It is critical that these treatments are compared in order to find those with the greatest efficacy. For this review, iscalimab seemed to have a greater reduction of disease activity than did ianalumab. Further studies with greater sample sizes are needed to conclude which has greater efficacy.